最大程度抑制前列腺癌患者的睾酮水平——游离睾酮与总睾酮。
Maximal testosterone suppression in prostate cancer--free vs total testosterone.
机构信息
Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora, CO.
Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora, CO.
出版信息
Urology. 2014 Jun;83(6):1217-22. doi: 10.1016/j.urology.2014.02.001. Epub 2014 Apr 6.
Abstract
Testosterone remains a key target in the treatment of advanced prostate cancer. The relationship of free testosterone to prostate cancer treatment and outcomes remains largely unexplored. A consensus of prostate cancer experts was convened in 2013 to review current knowledge surrounding relationship of total and free testosterone to prostate cancer, discuss the free hormone hypothesis, and highlight future avenues for therapeutics. Free testosterone may better reflect prostate cancer tissue androgen levels than serum total testosterone concentration. Free testosterone deserves more research regarding its relation to clinical outcomes.
摘要
睾酮仍然是治疗晚期前列腺癌的一个关键靶点。游离睾酮与前列腺癌治疗和结局的关系在很大程度上仍未得到探索。2013 年，召集了一批前列腺癌专家，以审查围绕总睾酮和游离睾酮与前列腺癌的关系的现有知识，讨论游离激素假说，并强调治疗的未来途径。游离睾酮可能比血清总睾酮浓度更能反映前列腺癌组织中的雄激素水平。游离睾酮与临床结局的关系值得进一步研究。
相似文献
1
Maximal testosterone suppression in prostate cancer--free vs total testosterone.最大程度抑制前列腺癌患者的睾酮水平——游离睾酮与总睾酮。
Urology. 2014 Jun;83(6):1217-22. doi: 10.1016/j.urology.2014.02.001. Epub 2014 Apr 6.
2
Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naïve Patients with Advanced Prostate Cancer?基线血清睾酮是否会影响激素初治的晚期前列腺癌患者的雄激素剥夺治疗结局？
J Urol. 2021 Mar;205(3):806-811. doi: 10.1097/JU.0000000000001413. Epub 2020 Oct 9.
3
Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.前列腺特异性抗原倍增时间可预测雄激素非依赖性前列腺癌男性患者对延迟抗雄激素治疗的反应。
Urology. 2004 Apr;63(4):732-6. doi: 10.1016/j.urology.2003.11.016.
4
Androgen deprivation therapy for prostate cancer.前列腺癌的雄激素剥夺疗法。
J Urol. 2007 Oct;178(4 Pt 1):1148. doi: 10.1016/j.juro.2007.07.066. Epub 2007 Aug 14.
5
Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.雄激素消除作为晚期前列腺癌的一种新治疗模式。
Curr Opin Urol. 2013 May;23(3):208-13. doi: 10.1097/MOU.0b013e32835fa889.
6
Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.初诊时睾酮水平低与前列腺癌特异性抗原失败及预后不良的前列腺癌患者死亡风险评估：前瞻性临床试验研究。
Cancer. 2018 Apr 1;124(7):1383-1390. doi: 10.1002/cncr.31204. Epub 2017 Dec 20.
7
Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.接受睾酮灭活药物间歇性治疗的前列腺癌男性患者的前列腺癌特异性生存率和无临床进展生存率。
Urology. 2007 Sep;70(3):506-10. doi: 10.1016/j.urology.2007.04.015.
8
Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.间歇性雄激素抑制治疗前列腺癌：初步报告。
Urology. 1995 May;45(5):839-44; discussion 844-5. doi: 10.1016/s0090-4295(99)80092-2.
9
Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.前列腺癌患者长期雄激素抑制后的睾酮恢复情况。
J Urol. 2008 Oct;180(4):1438-43; discussion 1443-4. doi: 10.1016/j.juro.2008.06.029. Epub 2008 Aug 16.
10
Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.血清睾酮水平预测抗雄激素序贯治疗在去势抵抗性前列腺癌患者中作为雄激素剥夺单药治疗二线治疗的疗效。
Jpn J Clin Oncol. 2011 Mar;41(3):405-10. doi: 10.1093/jjco/hyq193. Epub 2010 Oct 14.
引用本文的文献
1
Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer.在多西他赛耐药的转移性前列腺癌中，卡铂联合多西他赛化疗对睾酮水平及治疗结果的影响
Sci Rep. 2025 Jun 20;15(1):20130. doi: 10.1038/s41598-025-04667-0.
2
Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients.多西他赛诱导的游离睾酮血清水平抑制在转移性前列腺癌患者中的预后作用。
Sci Rep. 2021 Aug 12;11(1):16457. doi: 10.1038/s41598-021-95874-y.
3
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi).雌激素联合雄激素剥夺疗法治疗浸润性或转移性、去势敏感性前列腺癌：一项随机、双盲、II期试验（PCombi）
Eur Urol Open Sci. 2021 May 6;28:52-61. doi: 10.1016/j.euros.2021.04.005. eCollection 2021 Jun.
4
The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status.游离激素假说：何时、为何以及如何测量游离激素水平以评估维生素D、甲状腺、性激素和皮质醇状态。
JBMR Plus. 2020 Nov 2;5(1):e10418. doi: 10.1002/jbm4.10418. eCollection 2021 Jan.
5
How do we define "castration" in men on androgen deprivation therapy?在接受雄激素剥夺治疗的男性中，我们如何定义“去势”？
Asian J Androl. 2020 Sep-Oct;22(5):441-446. doi: 10.4103/aja.aja_139_19.
6
Estrogen therapy in patients with prostate cancer: a contemporary systematic review.前列腺癌患者的雌激素治疗：一项当代系统评价
Int Urol Nephrol. 2018 Jun;50(6):993-1003. doi: 10.1007/s11255-018-1854-5. Epub 2018 Mar 29.
7
Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?接受雄激素剥夺治疗的前列腺癌男性的报告及理想睾酮水平——是时候重新思考了？
Prostate Int. 2018 Mar;6(1):1-6. doi: 10.1016/j.prnil.2017.05.003. Epub 2017 Jun 20.
8
A novel model to predict positive prostate biopsy based on serum androgen level.基于血清雄激素水平预测前列腺活检阳性的新模型。
Endocr Relat Cancer. 2018 Jan;25(1):59-67. doi: 10.1530/ERC-17-0134. Epub 2017 Oct 18.
9
A Reappraisal of Testosterone's Binding in Circulation: Physiological and Clinical Implications.重新评估循环中睾酮的结合：生理和临床意义。
Endocr Rev. 2017 Aug 1;38(4):302-324. doi: 10.1210/er.2017-00025.
10
Steroid Hormone Receptors as Potential Mediators of the Clinical Effects of Dutasteride: A Prospective, Randomized, Double-Blind Study.作为度他雄胺临床效应潜在介导因子的类固醇激素受体：一项前瞻性、随机、双盲研究
Am J Mens Health. 2017 Jan;11(1):126-133. doi: 10.1177/1557988315602961. Epub 2016 Jul 8.
本文引用的文献
1
Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.药物或手术去势后的血清睾酮水平：文献综述
Urol Oncol. 2014 Jan;32(1):38.e17-28. doi: 10.1016/j.urolonc.2013.03.007. Epub 2013 Jun 13.
2
Intermittent versus continuous androgen deprivation in prostate cancer.前列腺癌的间歇性与连续性雄激素剥夺治疗。
N Engl J Med. 2013 Apr 4;368(14):1314-25. doi: 10.1056/NEJMoa1212299.
3
Genomic and epigenomic alterations in prostate cancer.前列腺癌中的基因组和表观基因组改变。
Front Endocrinol (Lausanne). 2012 Nov 6;3:128. doi: 10.3389/fendo.2012.00128. eCollection 2012.
4
Increased survival with enzalutamide in prostate cancer after chemotherapy.恩杂鲁胺可提高化疗后前列腺癌患者的生存率。
N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15.
5
Role of testosterone in managing advanced prostate cancer.睾酮在治疗晚期前列腺癌中的作用。
Urology. 2012 Oct;80(4):754-62. doi: 10.1016/j.urology.2012.05.006. Epub 2012 Jul 13.
6
[Change of the LHRH analogue in progressive castration-refractory prostate cancer].[进展性去势抵抗性前列腺癌中促性腺激素释放激素类似物的改变]
Urologe A. 2012 Sep;51(9):1282-7. doi: 10.1007/s00120-012-2948-9.
7
Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.黄体生成素释放激素激动剂治疗比手术去势导致的睾酮水平更低：质谱法获得的新见解。
J Urol. 2012 May;187(5):1601-6. doi: 10.1016/j.juro.2011.12.063. Epub 2012 Mar 14.
8
Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question.血清睪酮水平在接受 LH 释放激素治疗的前列腺癌患者中的变化：一个未解决的问题。
Endocr Relat Cancer. 2012 May 24;19(3):R93-8. doi: 10.1530/ERC-12-0040. Print 2012 Jun.
9
Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.戈舍瑞林与亮丙瑞林在前列腺癌患者去势治疗中的比较。
Int Urol Nephrol. 2012 Aug;44(4):1039-44. doi: 10.1007/s11255-012-0134-z.
10
Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.雄激素受体激活的分子状态：针对前列腺癌雄激素信号传导的治疗框架。
J Clin Oncol. 2012 Feb 20;30(6):644-6. doi: 10.1200/JCO.2011.39.1300. Epub 2011 Dec 19.
Zotero 插件